Brain cancer discovery reveals clues in quest for new therapies

May 10, 2017

Researchers have pinpointed two key molecules that drive the growth of an aggressive type of adult brain cancer.

The findings shed light on the mechanisms that underpin brain cancer progression and could eventually reveal targets for the development of much-needed therapies, researchers say.

Scientists conducted lab tests on tumour cells from patients with glioblastoma, a rare but aggressive type of brain cancer.

Previous studies have found that glioblastoma cells share similarities with normal brain stem cells, which give rise to the many different cell types in the brain during development.

The team identified two molecules that are produced at high levels by the cells - called FOXG1 and SOX2.

Similar levels of these molecules are found in brain stem cells and are a defining feature of these cells.

The researchers found that SOX2 drives glioblastoma cells to keep dividing, a hallmark of cancer.

FOXG1 stops the cells from responding to other signals that would usually point them towards becoming specialised, the team found.

Both FOXG1 and SOX2 work by controlling when key target genes are switched on and off by the cell.

The researchers analysed which genes were affected and identified several factors that are involved in controlling cell division.

The insights could open the door to new therapies that stop or slow tumour growth, the researchers say.

Glioblastoma is a fast-growing type of brain tumour. There are few options for treatment and only one in five patients will survive more than one year after diagnosis.

The study was led by scientists at the Medical Research Council Centre for Regenerative Medicine at the University of Edinburgh. The research is published in Genes and Development and was funded by Cancer Research UK and the Wellcome Trust.

Lead researcher Dr Steve Pollard, CRUK Senior Cancer Research Fellow at the University of Edinburgh, said: "Brain cancer cells seem to be hijacking important cell machinery that is used by normal brain stem cells. The tactic they appear to use is to produce high levels of these key regulators. This locks the tumour cells into perpetual cycles of growth and stops them listening to the signals that normally control cell specialisation."

Dr Áine McCarthy, Cancer Research UK's Senior Science Information Officer, said: "While survival for many types of cancer have improved dramatically, tackling brain tumours remains a challenge and we urgently need to develop new, kinder treatments.

"This research provides an exciting new insight into how two specific molecules might play a key role in driving the growth of glioblastoma tumours, the most common type of brain tumour. The next step will be for scientists to see if they can develop a way to stop glioblastoma cells from using these molecules as a way to survive and then to test it in clinical trials to see whether this affects tumour growth in people."
-end-


University of Edinburgh

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.